Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Carl Zeiss Meditec (AFXN) AI Stock Analysis

MX:AFXN

Carl Zeiss Meditec

(BMV:AFXN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Balance Sheet StrengthLow leverage and a robust equity ratio provide Carl Zeiss Meditec with financial resilience. This supports continued investment in ophthalmology and microsurgery products, gives management flexibility during weaker demand, and reduces the balance-sheet pressure associated with funding operations or growth.
Negative Factors
Revenue Growth PressureThe reported negative revenue-growth measure signals current top-line pressure and raises questions about near-term demand, commercial execution, or the pace of procedure-related equipment purchases. If sustained, slower sales would limit operating leverage and make future profit recovery more difficult.

Carl Zeiss Meditec (AFXN) vs. SPDR S&P 500 ETF (SPY)

-10%-5%0%5%10%15%20%MX:AFXN+0.85%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
MXN 65.64B
Dividend Yield
2.26%
Average Volume (3M)
―
Price to Earnings (P/E)
20.9
Beta (1Y)
-0.10
Revenue Growth
4.53%
EPS Growth
-34.57%
Country
Mexico
Employees
5,784
Sector
General
Sector Strength
55
Industry
Medical - Instruments & Supplies

Carl Zeiss Meditec Business Overview & Revenue Model

Company Description

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis...

Carl Zeiss Meditec Peers Comparison

Overall Rating

Financial Indicators

MX:AFXN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%0%0%1%1%MX:AFXNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
MX:AFXN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MX:AFXNCarl Zeiss Meditec1350.0011.420.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.